Connection

William Hrushesky to Doxorubicin

This is a "connection" page, showing publications William Hrushesky has written about Doxorubicin.
Connection Strength

0.810
  1. A recent illustration of some essentials of circadian chronotherapy study design. J Clin Oncol. 2004 Jul 15; 22(14):2971-2; author reply 2972.
    View in: PubMed
    Score: 0.204
  2. Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. Circulation. 1991 Aug; 84(2):697-707.
    View in: PubMed
    Score: 0.083
  3. Mammalian TIMELESS is required for ATM-dependent CHK2 activation and G2/M checkpoint control. J Biol Chem. 2010 Jan 29; 285(5):3030-4.
    View in: PubMed
    Score: 0.074
  4. Control of a murine plasmacytoma with doxorubicin-cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst. 1989 Jan 18; 81(2):135-45.
    View in: PubMed
    Score: 0.070
  5. Utility of non-invasive instantaneous screening test for drug-induced cardiac damage. J Clin Oncol. 1985 Oct; 3(10):1438-9.
    View in: PubMed
    Score: 0.056
  6. Modifying intracellular redox balance: an approach to improving therapeutic index. Lancet. 1985 Mar 09; 1(8428):565-7.
    View in: PubMed
    Score: 0.053
  7. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage. Am J Med. 1984 Sep; 77(3):399-406.
    View in: PubMed
    Score: 0.052
  8. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure. Chronobiol Int. 1984; 1(1):59-66.
    View in: PubMed
    Score: 0.049
  9. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995 Apr; 95(4):1650-9.
    View in: PubMed
    Score: 0.027
  10. Quantitative respiratory sinus arrhythmia analysis. A simple noninvasive, reimbursable measure of cardiac wellness and dysfunction. Ann N Y Acad Sci. 1991; 618:67-101.
    View in: PubMed
    Score: 0.020
  11. High-dose intensity, circadian-timed doxorubicin and cisplatin adjuvant chemotherapy for bladder cancer. Cancer Treat Rep. 1987 Oct; 71(10):915-9.
    View in: PubMed
    Score: 0.016
  12. High-dose intensity systemic therapy of metastatic bladder cancer. J Clin Oncol. 1987 Mar; 5(3):450-5.
    View in: PubMed
    Score: 0.015
  13. Chemotherapy-induced vomiting: circadian drug timing as a source of predictable within-patient variability. Cancer Treat Rep. 1986 Nov; 70(11):1347-8.
    View in: PubMed
    Score: 0.015
  14. Advanced transitional cell bladder cancer: a treatable disease. Semin Surg Oncol. 1986; 2(2):76-89.
    View in: PubMed
    Score: 0.014
  15. Lack of antiemetic effect of high-dose metoclopramide. J Clin Oncol. 1985 Sep; 3(9):1273-6.
    View in: PubMed
    Score: 0.014
  16. Circadian timing of cancer chemotherapy. Science. 1985 Apr 05; 228(4695):73-5.
    View in: PubMed
    Score: 0.013
  17. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology. 1984 Jul; 34(7):934-8.
    View in: PubMed
    Score: 0.013
  18. The clinical application of chronobiology to oncology. Am J Anat. 1983 Dec; 168(4):519-42.
    View in: PubMed
    Score: 0.012
  19. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin. Chronobiologia. 1980 Apr-Jun; 7(2):227-44.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.